论文信息 - A phase I trial of continuous infusion VP16-213 (Etoposide) - 字舞流文

A phase I trial of continuous infusion VP16-213 (Etoposide)

J. Aisner | P. Wiernik | M. Whitacre | D. A. Echo

[1] G. Hortobagyi,et al. Phase II study of VP16-213 (Etoposide) in refractory metastatic breast carcinoma , 2004, Cancer Chemotherapy and Pharmacology.

[2] F. Cavalli,et al. Pharmacokinetics of VP16-213 given by different administration methods , 2004, Cancer Chemotherapy and Pharmacology.

[3] L. Einhorn,et al. VP‐16–213 salvage therapy for refractory germinal neoplasms , 1980, Cancer.

[4] A. Barrett,et al. VP16-213 as a single agent in advanced testicular tumors. , 1980, European journal of cancer.

[5] P. Bunn,et al. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. , 1979, Cancer treatment reports.

[6] D. V. Von Hoff,et al. VM 26 and VP 16–213: A comparative analysis , 1977, Cancer.

[7] N. Nissen,et al. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. , 2009, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.